DEF 14A: Dogwood Therapeutics Seeks Shareholder Approval for Major Dilution

Dogwood Therapeutics, Inc. calls a special meeting to approve the conversion of non-voting preferred stock into common stock, significantly diluting existing shareholders, and to expand its equity incentive plan.

Summary

• A special meeting of stockholders is scheduled for November 21, 2025, to vote on five key proposals, including the conversion of three series of non-voting convertible preferred stock into common stock.
• The company seeks approval for the potential issuance of 22,691,494 shares of common stock upon conversion of Series A Preferred Stock, primarily issued to Sealbond Limited for the acquisition of the Halneuron development program.
• Approval is also sought for the potential issuance of 2,842,638 shares of common stock upon conversion of Series A-1 Preferred Stock, issued to Conjoint, Inc. (an affiliate of Sealbond Limited) in exchange for the cancellation of $19,926,891 in debt.
• A third proposal requests approval for the potential issuance of 1,900,572 shares of common stock upon conversion of Series A-2 Preferred Stock, issued to Serpin Pharma Inc. and Rejuvenation Labs, Inc. for the acquisition of the SP16 technology.
• The total common stock expected to be issued upon conversion of all preferred stock is 27,434,704 shares, which would increase the total outstanding common stock from 2,293,162 to 29,727,866 shares.
• The company also proposes to approve the Second Amended and Restated 2020 Equity Incentive Plan, increasing the shares available for issuance from 191,122 to 2,972,787.
• The final proposal is to approve the adjournment of the special meeting if necessary to solicit additional proxies or await Nasdaq approval of the Initial Listing Application.
• Pro forma financial information indicates a net loss of $(26,641,977) for the six months ended June 30, 2025, and $(24,259,396) for the year ended December 31, 2024, after giving effect to the licensing agreement and preferred stock conversions.

Sentiment

Score: 4

Explanation: The company is taking necessary steps to formalize its capital structure and incentivize management following significant acquisitions and debt conversion. However, the substantial pro forma losses and the massive dilution for existing common shareholders present a challenging outlook, indicating underlying financial weakness despite strategic moves.

Positives

• The conversion of preferred stock into common stock is presented as being in the best interest of the company, reflecting the economic contribution of acquired technologies (Halneuron and SP16) and the value of pain and neuropathy research programs.
• An increase in capitalization, supported by significant investors with industry experience, is expected to enhance the ability to continue and expand research programs, business and partnership development, and other strategic considerations.
• The Halneuron program, a first-in-class Nav 1.7 inhibitor, has been granted FDA fast-track review designation to treat chemotherapy-induced neuropathic pain, indicating potential for accelerated development.
• The expanded equity incentive plan aims to retain, recruit, and motivate key personnel, aligning their interests with those of stockholders and supporting the execution of corporate objectives.

Negatives

• The potential conversion of preferred stock will result in substantial dilution of the economic and voting interests of existing common stockholders, as their shares will represent a significantly smaller percentage of total outstanding shares.
• The sale of underlying common stock into the public market upon conversion could materially and adversely affect the market price of common stock.
• Failure to obtain stockholder approval for the preferred stock conversions would require the company to hold additional meetings, incurring significant legal expenses and diverting management's attention.
• Pro forma financial statements indicate substantial net losses, with $(26,641,977) for the six months ended June 30, 2025, and $(24,259,396) for the year ended December 31, 2024, highlighting ongoing operational challenges.

Risks

• The sale into the public market of the underlying common stock upon conversion of preferred stock could materially and adversely affect the market price of common stock.
• Existing stockholders' economic and voting interests will be diluted significantly if the preferred stock conversions are approved.
• Failure to obtain stockholder approval for the preferred stock conversions would necessitate continued stockholder meetings, leading to significant legal expenses and diversion of management attention.
• The Series A Preferred Stock is redeemable for cash at the option of the holder if certain events occur, including a futile interim analysis of the Phase 2b study for Halneuron, delisting from Nasdaq, or failure to complete the Phase 2b study by December 31, 2025, or by June 30, 2026.
• Pro forma financial information is based on assumptions and estimates that may not prove accurate, and actual results could differ materially.

Future Outlook

The company anticipates that an increase in its capitalization, supported by significant investors, will enhance its ability to continue and expand research programs, business and partnership development, and other strategic considerations. The board believes the conversion of preferred stock will better reflect the economic contribution of acquired technologies and the inherent value of pain and neuropathy research programs, including the late-stage Halneuron, which has FDA fast-track review designation.

Management Comments

• "Conversion of existing Dogwood Therapeutics, Inc. preferred stock into common stock and the associated increase in the Companys common stock capitalization are in the best interest of the Company and will better reflect the economic contribution of these technologies to the Company as well as the inherent value of our pain and neuropathy research programs, notably including our late stage Halneuron, a first-in-class Nav 1.7 inhibitor which has been granted FDA fast-track review designation to treat chemotherapy induced neuropathic pain."
• "An increase in Dogwood Therapeutics, Inc.s capitalization, underpinned by several significant investors with deep experience in our industry, enhances our ability to continue and expand the breadth of our research programs, business and partnership development and other strategic considerations moving forward."
• "The Board believes that equity awards are a key element underlying its ability to retain, recruit and motivate key personnel who are critical to our ability to execute successfully and implement our corporate objectives."

Industry Context

NA

Management Changes

Corporate Governance

Related Party Transactions

• Issuance of Series A Preferred Stock to Sealbond Limited (a wholly-owned subsidiary of CK Life Sciences Intl., (Holdings) Inc.) in connection with the Pharmagesic Combination.
• Issuance of Series A-1 Preferred Stock to Conjoint, Inc. (an affiliate of Sealbond Limited and indirect wholly-owned subsidiary of CK Life Sciences Intl., (Holdings) Inc.) in exchange for debt cancellation.
• Directors Melvin Toh and Alan Yu were designated for appointment to the Board by Sealbond Limited, highlighting their affiliation with a significant beneficial owner.

Stakeholder Impact

• **Shareholders:** Significant dilution of economic and voting interests due to the conversion of preferred stock into common stock. The market price of common stock could be adversely affected by the potential sale of these newly issued shares.
• **Management/Employees:** The expanded equity incentive plan provides increased opportunities for equity awards, aiming to improve retention, recruitment, and motivation, aligning their interests with company performance.
• **Preferred Stock Holders (Sealbond, Conjoint, Serpin, Rejuvenation):** Conversion into common stock will solidify their ownership and voting power, with Sealbond Limited and its affiliates potentially holding a controlling stake (73.4% post-conversion for Sealbond alone, and 90.4% for the group of four entities).
• **Regulatory Bodies (Nasdaq, SEC):** The company is seeking approvals to comply with Nasdaq Listing Rules 5635(a) and 5635(b) related to significant share issuances and potential change of control, ensuring regulatory adherence.

Next Steps

• Hold a Special Meeting of Stockholders on November 21, 2025, to vote on the proposed conversions of preferred stock, the amended equity incentive plan, and potential adjournment.
• If Proposal No. 1 is not approved, the company is required to use reasonable best efforts to secure approvals and hold annual or special meetings at least every six months until approvals are obtained.
• Seek a waiver of the Beneficial Ownership Limitation from holders of Series A and Series A-1 Preferred Stock, effective upon stockholder approval of the respective proposals.
• Continue the Phase 2b study for Halneuron, with an interim analysis expected by December 31, 2025, as its completion impacts the redeemability of Series A Preferred Stock.

Key Dates

Recommendation

The company is seeking shareholder approval for critical actions that will significantly reshape its capital structure and ownership. While these proposals are presented as necessary for strategic growth and management incentives, the immediate impact for existing common shareholders is substantial dilution (over 10x increase in outstanding shares) and a change of control. The pro forma financials also indicate significant ongoing losses. For existing investors, holding allows observation of the market's reaction to these approvals and the company's execution on its strategic initiatives post-restructuring. For new investors, a 'wait and see' approach is prudent until the full implications of this massive dilution and the company's path to profitability become clearer.

Keywords

Preferred Stock Conversion, Equity Incentive Plan, Nasdaq Listing Rules, Shareholder Approval, Dilution, Halneuron, SP16, Biotechnology, Pharmaceuticals, Corporate Governance, SEC Filing, Special Meeting, Pain and Neuropathy, FDA Fast-Track